6.11k followers • 18 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Bristol-Myers Squibb Company
Seattle Genetics, Inc.
Exact Sciences Corporation
Blueprint Medicines Corporation
Inovio Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc.
Foundation Medicine, Inc.
INSYS Therapeutics, Inc.
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.
The FDA bestows a Fast Track designation on Infinity's (INFI) IPI-549 in combination with Opdivo for treating advanced urothelial cancer. Stock rise.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
Zacks.com featured highlights include: Bristol-Myers Squibb, AmerisourceBergen, Leidos, Xcel Energy and Caseys General Stores
Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.
Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.
The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.